Champion AF Explained: Can LAA Closure Beat DOACs? Ft. Dr. Saibal Kar and Dr. Tom Waggoner

The Champion AF trial is one of the most important studies in structural heart — directly comparing left atrial appendage closure (LAAC) to DOAC therapy in patients with atrial fibrillation.In this MurmurMD discussion, Dr. Saibal Kar and Dr. Thomas Waggoner break down the Champion AF data, focusing on what the results actually mean for clinical practice and how they may shift long-term management strategies.Key themes from the transcript include:• The rationale behind comparing LAAC to DOAC therapy• Trial design and patient population• Key outcomes and how to interpret them• Safety and efficacy considerations• Where LAAC fits in the treatment algorithm today• How these results may impact future guidelines and patient selectionThis discussion offers a practical, real-world interpretation of a pivotal trial — and what it means for stroke prevention in atrial fibrillation moving forward.🔔 Subscribe for more insights from interventional experts and real-world program builders.📱 Download the app: https://apps.apple.com/app/apple-store/id1586692687📺 Follow us on YouTube: https://www.youtube.com/channel/UCfrLYhAhliQ2ZvXinkDCZvAChapters:00:00 – Overview of Champion AF and why it matters 01:00 – Trial design and patient selection 03:00 – Key outcomes and results interpretation 05:30 – Safety and procedural considerations 07:00 – LAAC vs DOAC: how to think about it clinically 08:30 – What this means for practice and future direction#ChampionAF #LAAClosure #AtrialFibrillation #StrokePrevention #StructuralHeart #Watchman #InterventionalCardiology #MurmurMD